Insiders' Blog
Sponsored by: Subscribe to EasyStockAlerts.com Now & Get The News Before Everyone Else!
Moody's Places Morgan Stanley (MS) Debt Under Review For Possible Downgrade
More News related to MS
- BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
- BioMS Medical announces its intention to renew a normal course issuer bid
- Ben Babcock Joins Morgan Stanley
- Analyst Reports for Occidental Petroleum Corporation, Advanced Micro Devices Inc., Morgan Stanley, and Coca-Cola Company
- Morgan Stanley Investment Management Launches Morgan Stanley Frontier Emerging Markets Fund, Inc.
Moody's Places Morgan Stanley (NYSE: MS) Debt Under Review For Possible Downgrade
According to Reuters, Moody's is reviewing Morgan Stanley's AA3 rating for a downgrade. Citing the firm's "expensive trading mishaps," Moody's says Morgan Stanley's long-term rating likely to be downgraded to A1.
Morgan Stanley is currently down around 1.5%.
Sign up at EasyStockAlerts.com To Be Alerted To Your Stock News Today!
Related Categories
Analyst CommentsInsiders' Blog
Trader Talk
Stocks Mentioned
+1.02Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
